The PRISM trial: Reply to the editor

Journal of Bone and Mineral Research

Volumn 25, Issue 6, 2010, Pages 1465-1466

  Ralston, Stuart ^a   Campbell, Marion ^a   Fraser, William D ^a   Langston, Anne L ^a   McLennan, Graeme ^a   Selby, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; BONE MALFORMATION; BONE PAIN; CLINICAL TRIAL; FRACTURE; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; LETTER; PAGET BONE DISEASE; QUALITY OF LIFE;

EID: 77953494824     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.97     Document Type: Letter

References (7)

1. Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH. Randomised trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res. 2010;25:20-31.
2. Langston AL, Campbell MK, Fraser WD, Maclennan G, Selby P, Ralston SH. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int. 2007;80:1-9. (Pubitemid 46095744)
3. Siris ES, Feldman F. Natural history of untreated Paget's disease of the tibia. J Bone Miner Res. 1997;12:691-692. (Pubitemid 27155230)
4. Ravault A, Meunier PJ. Long-term follow-up of 88 patients with Paget's disease treated by discontinuous courses of low-dose disodium etidronate. Rev Rhum Mal Osteoartic. 1989;56:293-302. (Pubitemid 19085364)
5. Rios-Petrakis M, Langston AL, Alonzo N, Selby PL, Fraser WD, Ralston SH. Mutations of SQSTM1 strongly predict disease severity and complications in Paget's disease of bone. Calcif Tissue Int. 2008;82:S26.
6. Smith R, Russell RGG, Bishop M. Diphosphonates and Paget's disease of bone. Lancet. 1971;1:945-947.
7. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353:898-908. (Pubitemid 41247929)